Immunome Reports $73.1 Million Net Loss in Q2 2026, Increased R&D Expenses

Immunome, Inc. reported significant financial results for the second quarter of 2026, revealing a net loss of $73.1 million, compared to a net loss of $43.4 million for the same period in 2025. The company's total operating expenses surged to $78.1 million, up from $50.5 million year-over-year, primarily driven by increased research and development costs, which rose to $59.9 million from $40.5 million. The absence of collaboration revenue, which was $4.0 million in the second quarter of 2025, contributed to the overall increase in losses. The net loss per share for the quarter was $0.65, compared to $0.50 in the prior year.

For the first half of 2026, Immunome's net loss reached $127.0 million, a substantial increase from $85.0 million in the same period of 2025. Total operating expenses for the six months ended June 30, 2026, were $137.5 million, compared to $98.1 million in the previous year. The increase in expenses was attributed to heightened research and development activities, particularly related to the advancement of its clinical pipeline, which includes the investigational drug varegacestat. The company has not yet generated any product revenue and does not anticipate doing so until it secures regulatory approval for its product candidates.

Immunome's strategic developments included the ongoing clinical trials for its lead product candidate, varegacestat, which has shown promising results in treating desmoid tumors. The company submitted a New Drug Application (NDA) for varegacestat in April 2026, which has been accepted by the FDA, with a target action date set for April 28, 2027. Additionally, Immunome is advancing other candidates, including IM-1021 and IM-1617, which are currently in Phase 1 trials. The company has also expanded its employee headcount to support these initiatives, reflecting its commitment to growth and development in the oncology sector.

As of June 30, 2026, Immunome reported cash and cash equivalents of $217.7 million and marketable securities totaling $302.3 million, down from $653.5 million in cash and cash equivalents at the end of 2025. The accumulated deficit increased to $855.1 million, highlighting the ongoing financial challenges faced by the company as it invests heavily in research and development. The company anticipates that its existing cash and marketable securities will be sufficient to fund operations for at least the next 12 months, but it may need to seek additional capital through equity offerings or collaborations to support its long-term objectives.

Looking ahead, Immunome remains focused on advancing its clinical pipeline and preparing for potential commercialization of its lead product, varegacestat. The company expects to incur significant expenses related to developing its sales and marketing capabilities, should it receive regulatory approval. Immunome's management continues to evaluate its funding requirements and may pursue various financing options to ensure the sustainability of its operations and research initiatives.